PDSB

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Principal, PDSB, NCI, Head, Survival, Associate, Incidence, Patient, National Cancer Institute, Cancer, Doctor of Philosophy, Biotechnology, Overalls, Oncology, Neck, ICI, Clinical trial, Immune system, IL-12, ICIS, FDA, Physician, PDS, Food, Pharmaceutical industry

This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.

Key Points: 
  • This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.
  • “We have had several discussions with key opinion leaders in HNSCC regarding the use of the triple combination in HNSCC.
  • The NCI clinical trial data show significant promise in the use of PDS01ADC in combination with Versamune® HPV,” said Katharine A.
  • The event will be archived on the Investor Relations section of PDS Biotech’s website for six months.

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, PDSB, Vaccine, Infection

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced that the Company will provide a business update and release financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024.

Key Points: 
  • PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced that the Company will provide a business update and release financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024.
  • Following the release, management will host a conference call to review the financial results and provide a business update.

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Retrieved on: 
Wednesday, March 13, 2024
CD4, PDSB, Infection, Patent, Influenza, Research, Virus, Biotechnology, Antibody, Intellectual property, Use, Viral, Vaccine

PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced the publication of preclinical research and a patent granted by the United States Patent and Trademark Office (USPTO) that strengthen the foundation of the Company’s infectious disease vaccine platform Infectimune®.

Key Points: 
  • The research concluded that Infectimune® is a leading candidate for use in the next generation of preventive vaccines that may provide more effective and broader protection than current vaccines allow.
  • Infectimune® is being used in PDS0202, the Company’s universal influenza vaccine intended to provide broad protection against multiple flu strains.
  • The patent protects compositions containing the Infectimune® platform and influenza antigens and methods of using the Infectimune® platform with pathogenic antigens generally.
  • “Possessing multiple layers of intellectual property for our assets is an important value driver for PDS Biotech and is a key component of our business strategy.”

Ontario's Largest School Boards Sue Social Media Giants for Disrupting Students' Fundamental Right to Education

Retrieved on: 
Thursday, March 28, 2024
PDSB, Cyberbullying, School, Attention, Snap Inc., OCDSB, Toronto District School Board, Learning, Achievement Medal, Aggression, Risk, Social media, Mental health, Behavior informatics, Ottawa-Carleton District School Board, TDSB, Student, Snapchat, Heart, Safety, Embury, ByteDance, TCDSB, Peel District School Board, Nursing

Students are experiencing an attention, learning, and mental health crisis because of prolific and compulsive use of social media products.

Key Points: 
  • Students are experiencing an attention, learning, and mental health crisis because of prolific and compulsive use of social media products.
  • This action calls on social media giants to remediate these enormous costs to the education system, to redesign their products to keep students safe.
  • Neinstein LLP, a Toronto-based boutique litigation firm, has been retained by the aforementioned school boards to represent them in their fight for social media change.
  • The goal of the litigation is to provide school boards with the resources needed to support student programming and services, and to respond to the school-based problems social media giants have caused.

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

Retrieved on: 
Monday, January 22, 2024
Senior, PDS, Employment, Cleveland Clinic, Hematology, Case Western Reserve University, University, Cancer, Boehringer Ingelheim, Infection, Cornell University, Baxter International, Retirement, Vaccine, Biotechnology, PDSB, Oncology

Dr. Shepard succeeds Lauren V. Wood, M.D., who is retiring from the Company after five years in the role.

Key Points: 
  • Dr. Shepard succeeds Lauren V. Wood, M.D., who is retiring from the Company after five years in the role.
  • Dr. Wood will continue to be available to PDS Biotech during a handover period to facilitate the transition of the role to Dr. Shepard.
  • “We are pleased to welcome Kirk to the PDS Biotech team.
  • Prior to joining PDS Biotech, Dr. Shepard was Chief Medical Officer, Senior Vice President and Head of the Global Medical Affairs Oncology Business Group at Eisai Pharmaceutical Company.

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

Retrieved on: 
Tuesday, January 16, 2024
Doctor of Philosophy, Infection, Vaccine, Conference, Biotechnology, PDSB

PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference taking place virtually on Thursday, January 18, 2024, at 10:00 AM EST.

Key Points: 
  • PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference taking place virtually on Thursday, January 18, 2024, at 10:00 AM EST.
  • Details are as follows:
    For more information about the conference, please contact your B. Riley representative directly.

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, December 4, 2023
Infection, Cancer, PDSB, Employment, PDS, Biotechnology

PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced today that on December 4, 2023, PDS Biotech granted nonstatutory stock options to Lars Boesgaard, the Company’s new Chief Financial Officer, to purchase a total of 200,000 shares of the Company’s common stock as a material inducement to Mr. Boesgaard’s employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech’s 2019 Inducement Plan, as amended, which was adopted on June 17, 2019 and provides for the granting of equity awards to new employees of PDS Biotech.

Key Points: 
  • PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced today that on December 4, 2023, PDS Biotech granted nonstatutory stock options to Lars Boesgaard, the Company’s new Chief Financial Officer, to purchase a total of 200,000 shares of the Company’s common stock as a material inducement to Mr. Boesgaard’s employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech’s 2019 Inducement Plan, as amended, which was adopted on June 17, 2019 and provides for the granting of equity awards to new employees of PDS Biotech.
  • The stock option has an exercise price of $5.28, the closing price of PDS Biotech’s common stock on December 4, 2023.
  • The stock option vests over a four-year period, with one-quarter of the shares vesting on the first anniversary of the grant date and the remaining shares vesting monthly over the 36-month period thereafter, subject to continued employment with the company through the applicable vesting dates.

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

Retrieved on: 
Tuesday, November 28, 2023
Copenhagen Business School, Health, Biotechnology, CFO, Business administration, Vaccine, PDSB, Alexion Pharmaceuticals, Doctor of Philosophy, Infection, Western University, PDS, IPO, Organization

“We are delighted to welcome Lars to the PDS Biotech team.

Key Points: 
  • “We are delighted to welcome Lars to the PDS Biotech team.
  • Prior to joining PDS Biotech, Mr. Boesgaard served as CFO of AM-Pharma B.V. from September 2021 to August 2023.
  • “I’m excited to join PDS Biotech as the company advances its robust pipeline of groundbreaking targeted cancer immunotherapies,” said Mr. Boesgaard.
  • “I look forward to working with the team to help drive PDS Biotech’s business strategy and financial growth.”

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Well, Neck, Annual general meeting, DNA, Cervical cancer, Castration, ICI, PSA, ADC, Patient, Research, Lymph, E pluribus unum, Neoplasm, Cytokine, Cancer, Pembrolizumab, Oncology, Doctor of Philosophy, OS, Burtness, Webcast, Safety, Fourth grade, Food, Head, International, Radiation, PDS, Infection, Society, SOC, PDSB, KOL, Opinion, National Cancer Institute, IL12, Recurrence, CRT, CD8, Ferret, Nivolumab, Squamous-cell carcinoma, Biomarker, Standard works, HDAC, Clinical trial, NCI, FDA, Biotechnology, Vaccine, Prostate cancer, Immunotherapy, Survival, TH1, Prostate-specific antigen, Cetuximab, HPV, Docetaxel, Pharmaceutical industry, Medical imaging, Birth control, H1N1

The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.

Key Points: 
  • The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.
  • PDS Biotech anticipates initiation of VERSATILE-003 in Q1 2024.
  • PDS Biotech’s cash balance as of September 30, 2023 was approximately $54.3 million.
  • PDS Biotech believes that, with initiating the VERSATILE-003 Phase 3 clinical trial in the first quarter of 2024, its available cash resources will sustain operational and research and development endeavors into the third quarter of 2024.

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, Surgery, General Health, Health, Medical Devices, Health Technology, Technology, Other Technology, CFO, Plasma, Cardiac electrophysiology, Accounting, Strata Skin Sciences, Lehigh University, Senior, Marketing, Financial management, Forecasting, Cantel Medical Corporation, Growth, PDSB, EP, Pharmaceutical industry, Nursing, Science

Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023.

Key Points: 
  • Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023.
  • Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023.
  • “Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies,” said Charlie Goodwin, President and Chief Executive Officer of Apyx Medical.
  • “I am pleased to join the Company at this exciting time, and look forward to working with Charlie and the rest of the team as we lead Apyx Medical through its next stage of growth and development.”
    Mr. Hill joins Apyx Medical from PDS Biotechnology Corporation (Nasdaq: PDSB; “PDS Biotech”), a clinical-stage immunotherapy company, where he served as Chief Financial Officer, leading all aspects of the company’s budgeting, forecasting, financial management and reporting.